Safety and immunogenicity of intranasal murine parainfluenza virus type I (Sendai virus) in healthy human adults
Safety and immunogenicity of intranasal murine parainfluenza virus type I (Sendai virus) in healthy human adults
复制标题
DOI：
10.1016/j.vaccine.2004.01.053
复制
发表时间：
2004-08-13
期刊：
影响因子：
5.5
通讯作者：
Hurwitz, JL
中科院分区：
文献类型：
--
作者：
Slobod, KS;Shenep, JL;Hurwitz, JL
人类副流感病毒1型(hPIV-1)是儿科喉气管支气管炎(Croup)最常见的原因，每年导致近30,000名美国人住院[Ped.信息迪什。J.20(2001)646]。目前还没有有效的疫苗可用。在第一阶段的健康成人剂量递增研究中，我们检验了小鼠PIV-1(仙台病毒，SeV)作为密切相关的人类PIV-1的异种活疫苗。鼻腔内仙台病毒的耐受性一致良好，并在九名疫苗接种者中的三名中显示出免疫原性的证据，尽管先前可能因接触人类PIV-1而诱导了预先存在的交叉反应免疫。结果鼓励未来的试验，以评估仙台病毒在预防婴儿和儿童感染人类PIV-1病毒的有效性。(C)2004爱思唯尔有限公司。保留所有权利。
Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of pediatric laryngotracheobronchitis (croup) and results in close to 30,000 US hospitalizations each year [Ped. Inf. Dis. J. 20 (2001) 646]. No effective vaccine is available. We examined murine PIV-1 (Sendai virus, SeV) as a live, xenotropic vaccine for the closely related human PIV-1 in a phase 1, dose escalation study in healthy adults. Intranasal Sendai virus was uniformly well-tolerated and showed evidence of immunogenicity in three of nine vaccinees despite pre-existing, cross-reactive immunity presumably induced by previous exposure to human PIV-1. Results encourage future trials to evaluate the efficacy of Sendai virus in preventing human PIV-1 infection in infants and children. (C) 2004 Elsevier Ltd. All rights reserved.